Scynexis (SCYX) Income towards Parent Company (2013 - 2026)
Scynexis (SCYX) posted Income towards Parent Company of -$16.4 million for Q1 2026, down 234.03% on a QoQ basis from $12.3 million in Q4 2025, and down 204.75% year-over-year from $15.7 million in Q1 2025.
Scynexis (SCYX) Income towards Parent Company (2013 - 2026) Analysis & Trends
Scynexis' Income towards Parent Company history runs 13 years deep, the most recent figure standing at -$16.4 million for Q1 2026.
- Quarterly Income towards Parent Company fell 204.75% year-over-year to -$16.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.6 million (up 27.61% YoY) and the FY2025 annual result came in at -$8.6 million, up 59.65% from the prior year.
- Income towards Parent Company was -$16.4 million for Q1 2026 at Scynexis, down from $12.3 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $122.3 million in Q2 2023 and bottomed at -$33.9 million in Q1 2023.
- A 5-year average of -$2.9 million and a median of -$6.9 million in 2025 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company plunged 4789.92% — and 2023, when it soared 1016.15%.
- Scynexis' Income towards Parent Company stood at -$19.5 million in 2022, then dropped by 9.06% to -$21.3 million in 2023, then surged by 78.92% to -$4.5 million in 2024, then surged by 373.49% to $12.3 million in 2025, then plunged by 234.03% to -$16.4 million in 2026.
- Business Quant data shows SCYX's Income towards Parent Company at -$16.4 million in Q1 2026, $12.3 million in Q4 2025, and -$8.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Scynexis | 23.19 Mn | -13.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.43 Mn |
| Dec 31, 2025 | 12.26 Mn |
| Sep 30, 2025 | -8.59 Mn |
| Jun 30, 2025 | -6.89 Mn |
| Mar 31, 2025 | -5.39 Mn |
| Dec 31, 2024 | -4.48 Mn |
| Sep 30, 2024 | -2.81 Mn |
| Jun 30, 2024 | -14.46 Mn |
| Mar 31, 2024 | 411,000.00 |
| Dec 31, 2023 | -21.27 Mn |
| Sep 30, 2023 | -1.76 Mn |
| Jun 30, 2023 | 122.26 Mn |
| Mar 31, 2023 | -33.88 Mn |
| Dec 31, 2022 | -19.50 Mn |
| Sep 30, 2022 | -29.58 Mn |
| Jun 30, 2022 | -13.35 Mn |
| Mar 31, 2022 | -5.45 Mn |
| Dec 31, 2021 | -29.28 Mn |
| Sep 30, 2021 | -605,000.00 |
| Jun 30, 2021 | 1.66 Mn |